A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 23 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Savolitinib (Primary) ; Sunitinib
Indications Renal cell carcinoma
Focus Registrational; Therapeutic Use
Acronyms SAVOIR
Sponsors AstraZeneca

Most Recent Events

16 Jan 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
13 Jan 2023 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.
19 Nov 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight